Lexaria Bioscience

Lexaria Bioscience Days Inventory Outstanding

The Days Inventory Outstanding (DIO) of Lexaria Bioscience (LEXX) as of Nov 5, 2026 is 0.01. In the previous year, Days Inventory Outstanding (DIO) was 195.19 — a change of -99.99% (lower).

Days Inventory Outstanding

0.01

YoY

-99.99%

Last updated:

Days Inventory Outstanding (DIO) of Lexaria Bioscience is 2023 0.01 . Days Inventory Outstanding (DIO) of Lexaria Bioscience was 2022 195.19 . It decreases by -99.99% lower compared to the previous year.

The Lexaria Bioscience Days Inventory Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Inventory Outstanding
Date
Days Inventory Outstanding
Jan 1, 2016
1,078.03 USD
Jan 1, 2017
824.15 USD
Jan 1, 2018
1,264.25 USD
Jan 1, 2019
2,031.17 USD
Jan 1, 2020
429.25 USD
Jan 1, 2021
61.72 USD
Jan 1, 2022
195.19 USD
Jan 1, 2023
0.01 USD
The Lexaria Bioscience Days Inventory Outstanding history
YEARDays Inventory OutstandingYoY
0.01-99.99%
195.19+216.27%
61.72-85.62%
429.25-78.87%
2,031.17+60.66%
1,264.25+53.40%
824.15-23.55%
1,078.03-47.46%
2,051.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lexaria Bioscience Stock analysis

What does Lexaria Bioscience do? Lexaria Bioscience Corp. generates revenue through its DehydraTECH drug delivery technology, which enhances the bioavailability of active pharmaceutical ingredients. The company operates in two segments: Intellectual Property and Products, licensing its patented technology to partners in the pharmaceutical industry. DehydraTECH formulations improve oral absorption and have demonstrated enhanced delivery into brain tissue, supporting applications for intraoral and topical administration. The firm holds 35 granted patents and numerous pending patents worldwide, leveraging its intellectual property portfolio for licensing agreements. The company's primary customers are pharmaceutical firms seeking to improve drug delivery for oral, intraoral, and topical formulations. These partners utilize DehydraTECH to increase the effectiveness of active molecules, particularly for applications requiring higher bioavailability or targeted brain delivery. Lexaria's technology is positioned to support the development of new pharmaceutical products without direct manufacturing involvement. Lexaria's business model relies on licensing its patented DehydraTECH technology to pharmaceutical companies, generating income through intellectual property agreements. The company does not produce or sell finished pharmaceutical products but instead focuses on technology licensing and intellectual property management. Its subsidiary Lexa is part of the corporate structure but does not drive revenue generation. Lexaria Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lexaria Bioscience stock

Days Inventory Outstanding (DIO) of Lexaria Bioscience is 0.01 in 2023.

Days Inventory Outstanding (DIO) of Lexaria Bioscience changed from 195.19 to 0.01, representing a -99.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Inventory Outstanding (DIO) Lexaria Bioscience since 2006 – with annual values, charts, and detailed analysis.

DIO measures the average number of days inventory is held before being sold. Lower values indicate more efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Inventory Outstanding (DIO)'s Lexaria Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Inventory Outstanding (DIO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Inventory Outstanding (DIO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Lexaria Bioscience

All Key Metrics — Lexaria Bioscience